The risk of distant metastases and cancer-specific survival in men with serum prostate-specific antigen values above 100 ng/ml.

PURPOSE - Current European Association of Urology guidelines state that a PSA≥100 ng/ml at diagnosis indicates metastatic disease. The aim of the present study was to examine the association between PSA values ≥100 ng/ml at diagnosis, distant metastasis and prostate cancer-specific survival.

MATERIALS AND METHODS - 15,635 men with prostate cancer diagnosed between 1998 and 2009 identified in the Prostate Cancer Data Base Sweden (PCBaSe) were included in a population-based register study. Prostate cancer-specific survival was compared between three groups: 1,879 men with PSA ≥100 ng/ml and negative imaging investigations (M0); 5,642 men with distant metastases on imaging (M1) and PSA ≥ 100 ng/ml, and 3,828 men with M1 and PSA < 100 ng/ml. A fourth group consisted of 4,286 men with PSA ≥ 100 ng/ml who had not undergone imaging (Mx), but were not included in the assessment of survival.

RESULTS - Of 7,521 men with PSA≥100 ng/ml undergoing imaging for staging, 26% were classified as M1. Only 59% of 3,527 men with PSA 100-300mg/ml had distant metastases on imaging. The 5-year prostate cancer-specific survival was 72% (95% confidence interval [CI] 70-74%) in men with PSA≥100 ng/ml and M0, 24% (95% CI 23-25%) in men with PSA≥100 ng/ml and M1, and 39% (95% CI 37-40%) in men with PSA

CONCLUSIONS - One fourth of men with PSA values ≥100 ng/ml did not have distant metastases and had a 2-3 fold higher 5-year survival than men with distant metastases on imaging. Our findings strongly suggest that the use of PSA≥100 ng/ml as indicator of metastatic disease should be reconsidered.

J Urol. 2015 Jul 17. pii: S0022-5347(15)04415-8. doi: 10.1016/j.juro.2015.07.082. [Epub ahead of print]

Stattin K1, Sandin F2, Bratt O3, Lambe M4.

1 Department of Surgical Sciences, Uppsala University, Sweden.
2 Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden.
3 Urological Cancer Research Unit, Department of Translational Medicine, Lund University , Sweden; Department of Urology, Cambridge Hospitals, United Kingdom.
4 Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe